GH Stock Forecast & Price Target

Guardant Health has demonstrated impressive revenue growth, with a two-year CAGR of +28% projected from 2023 to 2025, driven by strengths in colorectal cancer (CRC), breast cancer, and new monitoring applications, as well as ongoing expansion in reimbursement coverage. The company's recent FDA approval of the Shield test for colorectal cancer screening has contributed to an increased annual revenue guidance, reflecting an anticipated 31% year-over-year growth. Additionally, the company's stock performance, with shares increasing by +136% year-to-date and a market capitalization poised to exceed $10 billion, positions Guardant Health as an attractive investment opportunity supported by strong growth projections and expanding product offerings.

Guardant Health faces a negative outlook primarily due to underwhelming revenue guidance for its Shield product, which has not met investor expectations for medium-term growth. The company reported an adjusted EBITDA loss of $45.5 million in the third quarter of 2025, indicating ongoing financial challenges that may impact future profitability. Furthermore, any adverse developments related to regulatory approvals, reimbursement outcomes, or product launch timings could further exacerbate the stock's volatility and investor sentiment.